Latest Biotech News

Ahead of ASCO 2026, abstract “snapshots” released by conference organizers are spotlighting oncology strategies that expand beyond KRAS in pancreatic cancer. Coverage also points to strong...

Parabilis filed for an initial public offering one day after signing a strategic collaboration with Regeneron that could reach up to $2.3 billion. The deal centers on “antibody-Helicon...

Biocentury coverage points to Q’s proposed €5 billion cross-sector growth fund as a potential tool to narrow Europe’s biotech capital gap. The concept is aimed at increasing the availability of...

New preclinical work indicates that targeting cholesterol transport enzymes could suppress tumor growth by starving cancer cells of needed lipid trafficking. Researchers reported that blocking...

Researchers described an interpretable machine-learning model intended for early detection of pediatric sepsis using routine lab inputs. By emphasizing explainability, the approach aims to make...

The WHO and CDC ramped up diagnostic testing for Bundibugyo Ebola as the outbreak in the DRC escalated in spread risk. WHO raised the threat level from High to Very High after assessing the...

AbbVie announced a new round of 85 layoffs tied to its Irvine, California site within its eye-care business, effective July 20. The WARN notice continues a pattern of workforce adjustments at the...

University of Pennsylvania investigators and clinicians discussed the Philadelphia “Baby KJ” CRISPR base-editing case study, characterizing it as a single-patient expanded access effort rather...

FDA has granted approval to Gilead’s hepatitis D therapy Hepcludex (bulevirtide) after the agency previously rejected the drug over manufacturing and distribution issues. The decision reopens a...

FDA approved Daiichi Sankyo and AstraZeneca’s TROP2-directed antibody-drug conjugate Datroway (datopotamab deruxtecan-dlnk) for adults with unresectable or metastatic triple-negative breast cancer...

AstraZeneca’s breast cancer drug received positive momentum from European regulators despite a negative vote from an FDA advisory committee last month, according to the report. The European...

Immuneering reported phase IIa results showing a 17.3-month median overall survival for first-line metastatic pancreatic cancer patients treated with its MEK inhibitor atebimetinib (IMM-1-104)...

Updated phase 3 findings for dostarlimab plus carboplatin and paclitaxel in dMMR/MSI-H endometrial cancer show durable disease control, with full data expected at ASCO 2026. The update draws from...

University of Pennsylvania and Children’s Hospital of Philadelphia reported meaningful clinical benefits from an mRNA-based CRISPR base-editing therapy delivered to “Baby KJ,” an infant with CPS1...

Parabilis filed for an initial public offering one day after signing an up-to-$2.3 billion-plus strategic research collaboration with Regeneron. The deal centers on discovery and development of...

Seegene obtained CE IVDR marking for its Allplex MDRO Assay, a multiplex real-time PCR test for detecting multidrug-resistant organisms and associated resistance genes linked to...

Oorja Bio secured $30 million in a Series A round from founding investor Westlake Biopartners to advance its in-licensing drug pipeline for idiopathic pulmonary fibrosis (IPF) and other fibrotic...

Vizgen laid off an undisclosed number of employees as part of a strategic reorganization, according to the company’s statement and reports from affected workers. The spokesperson said the firm is...

The FDA cleared Gilead’s hepatitis D therapy Hepcludex (bulevirtide) after a prior rejection tied to manufacturing and distribution issues, giving the first real regulatory foothold for chronic...

Dostarlimab plus chemotherapy showed durable disease control in dMMR/MSI-H endometrial cancer, with updated RUBY trial data released ahead of ASCO 2026. At a median follow-up of 55.6 months,...